166 related articles for article (PubMed ID: 35016028)
61. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
Gadgeel SM
Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
[No Abstract] [Full Text] [Related]
62. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
de Castro-Carpeño J; Perona R; Belda-Iniesta C
Clin Transl Oncol; 2011 Nov; 13(11):774-9. PubMed ID: 22082640
[TBL] [Abstract][Full Text] [Related]
63. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
[TBL] [Abstract][Full Text] [Related]
64. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
[TBL] [Abstract][Full Text] [Related]
65. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S
Crit Rev Oncol Hematol; 2018 Feb; 122():150-156. PubMed ID: 29458783
[TBL] [Abstract][Full Text] [Related]
66. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
Camidge DR; Kono SA; Flacco A; Tan AC; Doebele RC; Zhou Q; Crino L; Franklin WA; Varella-Garcia M
Clin Cancer Res; 2010 Nov; 16(22):5581-90. PubMed ID: 21062932
[TBL] [Abstract][Full Text] [Related]
67. Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.
Li Z; Lin Y; Chi X; Xu M; Wang H
Lung Cancer; 2021 Mar; 153():174-175. PubMed ID: 33472762
[No Abstract] [Full Text] [Related]
68. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
69. Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.
Davis LE; Nusser KD; Przybyl J; Pittsenbarger J; Hofmann NE; Varma S; Vennam S; Debiec-Rychter M; van de Rijn M; Davare MA
Mol Cancer Res; 2019 Mar; 17(3):676-685. PubMed ID: 30518629
[TBL] [Abstract][Full Text] [Related]
70. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
71. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
Iams WT; Lovly CM
Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
[TBL] [Abstract][Full Text] [Related]
72. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
73. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
74. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
75. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
[TBL] [Abstract][Full Text] [Related]
76. Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand.
McKeage MJ; Tin Tin S; Khwaounjoo P; Sheath K; Dixon-McIver A; Ng D; Sullivan R; Cameron L; Shepherd P; Laking GR; Kingston N; Strauss M; Lewis C; Elwood M; Love DR
Intern Med J; 2020 Jun; 50(6):716-725. PubMed ID: 31318119
[TBL] [Abstract][Full Text] [Related]
77. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract][Full Text] [Related]
78. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
79. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
80. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
